USFDA Warning Letter for Baddi facility, no impact on operations

Regulatory & Legal View source PDF Explain this filing

ZYDUSLIFE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.4%Reaction day

₹1080.00

prior close

₹1063.20

announcement price

In-mkt

timing

Nifty 100market · index membership as recorded later (tracked since Jun 2026)-0.3%-0.0% vs market

Pharmaceuticals peers, median of 163sector-0.0%-0.4% vs sector

On the reaction day the stock moved in line with Nifty 100 and 0.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.8

10m

-0.7

15m

-0.8

30m

-0.8

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.4-0.3-0.0-0.0-0.4

Next day

+0.4-0.3+0.6+0.2+0.1

+1.0-0.4+1.4+0.5+0.5

+0.6-1.6+2.2-0.2+0.8

+2.2-0.9+3.0+0.7+1.4

+1.6-1.2+2.8+0.1+1.5

+2.1+0.5+1.7+0.8+1.3

15d

+1.5+2.4-0.9+4.6-3.0

+5.4+3.3+2.1+6.5-1.1

+3.3+5.7-2.4+6.8-3.5

+5.6+2.1+3.5+8.1-2.5

UpDownMarket · Nifty 100Sector · Pharmaceuticals peers, median of 163Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Zydus Lifesciences received a USFDA Warning Letter for its formulation manufacturing facility at Baddi, Himachal Pradesh. The letter was issued in response to a records request under section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act, not from an on-site inspection. It cites technical observations about purified talc not meeting current US Pharmacopeia requirements. The company says this will not impact current operations or supplies from the Baddi site. The facility was last inspected in August 2025 and classified as VAI in October 2025. Zydus will work with USFDA on remediation within stipulated timelines.

Likely market impact

Procedural warning, not an import alert. Company says no supply or operational impact, but near-term sentiment may be mildly negative.